Table 2.
The effect of plasma homocysteine levels on cardiometabolic multimorbidity and its attribution risk percentage based on 1:1 matching case–control studya.
| Homocysteine (mmol/L) | NO-CMM vs. CMM | ||
|---|---|---|---|
| OR | 95%CI | p-value | |
| Q1 | 1.00 | ||
| Q2 | 1.16 | 0.73–1.84 | 0.535 |
| Q3 | 1.50 | 0.95–2.38 | 0.083 |
| Q4 | 2.83 | 1.84–4.36 | <0.001 |
| Trend for per unit | 1.12 | 1.08–1.16 | <0.001 |
| ARP (%, 95CI) | 64.66 | 46.24–77.06 | |
a
Adjusted for age, sex, educational attainment, family income, occupation status, marital status, current smoking, heavy alcohol consumption, unhealthy diet, inactive exercise, sedentary behavior, BMI, WC, TC, TG, LDL-C and HDL-C.